Differential effects of MAPKs signaling on the growth of invasive bladder cancer cells

International Journal of Oncology

Volumn 34, Issue 6, 2009, Pages 1557-1564

  Kumar, Binod ^a   Sinclair, Jane ^a   Khandrika, Lakshmipathi ^a   Koul, Sweaty ^a   Wilson, Shandra ^a   Koul, Hari K ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Bladder cancer; Cell cycle; Cell death; Mitogen activated protein kinase

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CYCLIN B1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE TARGETING; GROWTH CURVE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLAVONOIDS; HUMANS; IMIDAZOLES; IMMUNOENZYME TECHNIQUES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 67649422146     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000285     Document Type: Article

References (20)

1. Knowles MA: Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 27: 361-373, 2006.
2. Al-Sukhun and Hussain M: Current understanding of the biology of advanced bladder cancer. Cancer 97: 2064-2075, 2003.
3. Swiatkowski S, Seifert HH, Steinhoff C, et al: Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. Exp Cell Res 282: 48-57, 2003.
4. Billerey C, Chopin D, Aubriot-Lorton MH, et al: Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158: 1955-1959, 2001.
5. Sibley K, Cuthbert-Heavens D and Knowles MA: Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene 20: 686-691, 2001.
6. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF and Knowles MA: FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24: 5218-5225, 2005.
7. Schubbert S, Shannon K and Bollag G: Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7: 295-308, 2007.
8. Doherty SC, McKeown SR, McKelvey-Martin V, et al: Cell cycle checkpoint function in bladder cancer. J Natl Cancer Inst 95: 1859-1868, 2003.
9. Kumar B, Joshi J, Kumar A, Pandey BN, Hazra B and Mishra KP: Radiosensitization by diospyrin diethylether in MCF-7 breast carcinoma cell line. Mol Cell Biochem 304: 287-296, 2007.
10. Barton KN, Paielli D, Zhang Y, et al: Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol Ther 13: 347-356, 2006.
11. Koul HK, Menon M, Chaturvedi LS, et al: COM crystals activate the p38 mitogen-activated protein kinase signal transduction pathway in renal epithelial cells. J Biol Chem 277: 36845-36852, 2002.
12. Schmitt CA and Lowe SW: Apoptosis and chemoresistance in transgenic cancer models. Mol Med 80: 137-146, 2002.
13. Li SP, Junttila MR, Han J, Kähäri VM and Westermarck J: p38 mitogen-activated protein kinase pathway suppresses cell survival by inducing dephosphorylation of mitogen-activated protein/extracellular signal-regulated kinase kinase 1,2. Cancer Res 63: 3473-3477, 2003.
14. Lipponen P and Eskelinen M: Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and longterm prognosis. Br J Cancer 69: 1120-1125, 1994.
15. Ravery V, Colombel M, Popov Z, et al: Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer. Br J Cancer 71: 196-200, 1995.
16. Krüger S, Weitsch G, Büttner H, et al: Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol 21: 981-987, 2002.
17. Knight RD, Parshad R, Price FM, Tarone RE and Sanford KK: X-ray-induced chromatid damage in relation to DNA repair and cancer incidence in family members. Int J Cancer 54: 589-593, 1993.
18. Bose B, Motiwale L and Rao KV: DNA damage and G2/M arrest in Syrian hamster embryo cells during Malachite green exposure are associated with elevated phosphorylation of ERK1 and JNK1. Cancer Lett 230: 260-270, 2005.
19. Yuan J, Yan R, Krämer A, et al: Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene 23: 5843-5852, 2004.
20. Aranha O, Wood DP Jr and Sarkar FH: Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res 6: 891-900, 2000.